FibroGen Inc Banner Image

FibroGen Inc

  • Ticker FGEN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
FibroGen Inc Logo Image
  • 201-500 Employees
  • Based in San Francisco, California
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing roxadustat, or FG-4592, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; FG-3019More, a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage.
FibroGen Inc

Most Recent Annual Report

FibroGen Inc MOST RECENT 2019 Annual Report and Form 10K

Report Locked. FibroGen Inc has reached its limit for free report views.

Older/Archived Annual Reports